Eyepoint Pharmaceuticals Valuation
| EYPT Stock | USD 8.25 0.21 2.48% |
At this time, the firm appears to be undervalued. Eyepoint Pharmaceuticals shows a prevailing Real Value of $14.05 per share. The current price of the firm is $8.25. Our model computes the value of Eyepoint Pharmaceuticals from reviewing the firm fundamentals such as Shares Outstanding of 68.25 M, profit margin of (2.27) %, and Current Valuation of 372.15 M as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Eyepoint Pharmaceuticals' valuation include:
Price Book 2.7614 | Enterprise Value 372.2 M | Enterprise Value Ebitda (11.49) | Price Sales 13.2134 | Enterprise Value Revenue 8.141 |
Undervalued
Today
Please note that Eyepoint Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Eyepoint Pharmaceuticals is based on 3 months time horizon. Increasing Eyepoint Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Eyepoint Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 8.25, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.25 | Real 14.05 | Target 31.75 | Hype 8.37 | Naive 9.48 |
The intrinsic value of Eyepoint Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Eyepoint Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Eyepoint Pharmaceuticals helps investors to forecast how Eyepoint stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Eyepoint Pharmaceuticals more accurately as focusing exclusively on Eyepoint Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Eyepoint Pharmaceuticals' intrinsic value based on its ongoing forecasts of Eyepoint Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Eyepoint Pharmaceuticals' closest peers.
Eyepoint Pharmaceuticals Cash |
|
Eyepoint Valuation Trend
Eyepoint Pharmaceuticals' real value is important for investors to make better decisions and a more accurate overall view of Eyepoint Pharmaceuticals' financial worth over time. Using both Eyepoint Pharmaceuticals' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Eyepoint Revenue by Product
Eyepoint Pharmaceuticals Total Value Analysis
Eyepoint Pharmaceuticals is currently projected to have valuation of 372.15 M with market capitalization of 604.02 M, debt of 4.91 M, and cash on hands of 171.17 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Eyepoint Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
372.15 M | 604.02 M | 4.91 M | 171.17 M |
Eyepoint Pharmaceuticals Investor Information
About 93.0% of the company shares are held by institutions such as insurance companies. The book value of Eyepoint Pharmaceuticals was currently reported as 4.09. The company recorded a loss per share of 1.99. Eyepoint Pharmaceuticals last dividend was issued on the 9th of December 2020. The entity had 1:10 split on the 9th of December 2020. Based on the key indicators related to Eyepoint Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Eyepoint Pharmaceuticals may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.Eyepoint Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Eyepoint Pharmaceuticals has an asset utilization ratio of 12.96 percent. This implies that the Company is making $0.13 for each dollar of assets. An increasing asset utilization means that Eyepoint Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Eyepoint Pharmaceuticals Ownership Allocation
Eyepoint Pharmaceuticals holds a total of 68.25 Million outstanding shares. The majority of Eyepoint Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Eyepoint Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Eyepoint Pharmaceuticals. Please pay attention to any change in the institutional holdings of Eyepoint Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Eyepoint Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 46.02 M. Net Loss for the year was (70.8 M) with profit before overhead, payroll, taxes, and interest of 26.95 M.About Eyepoint Pharmaceuticals Valuation
The stock valuation mechanism determines Eyepoint Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Eyepoint Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Eyepoint Pharmaceuticals. We calculate exposure to Eyepoint Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Eyepoint Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 41.4 M | 43.5 M | |
| Pretax Profit Margin | (1.54) | (1.61) | |
| Operating Profit Margin | (1.63) | (1.71) | |
| Net Loss | (1.54) | (1.62) | |
| Gross Profit Margin | 0.90 | 0.94 |
Eyepoint Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Eyepoint Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 38.9 M |
Eyepoint Pharmaceuticals Current Valuation Indicators
Eyepoint Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Eyepoint Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Eyepoint Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Eyepoint Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Eyepoint Pharmaceuticals' worth.Additional Tools for Eyepoint Stock Analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.